The global biomaterials market size was estimated at USD 155.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 15.52% from 2023 to 2030. The rising prevalence of musculoskeletal and chronic skeletal medical conditions are expected to boost the demand for biomaterial-based implants, thereby augmenting the market growth. The demand for orthopedic implants is also rising owing to the increasing geriatric population, at an increased risk of osteoarthritis, osteoporosis, and other musculoskeletal disorders. The development of various biomaterial and biomedical devices are in demand for detecting and treating the coronavirus. In this pandemic, early detection of the virus is very crucial to limit the transmission of the same. The infection from the COVID-19 can be detected using existing biomedical devices which are based on either Polymerase Chain Reaction (PCR) or Non-PCR methods.
Biomaterial Technologies contribute to the development of new efficient personal protective equipment, drug deliveries, vaccines, and new therapeutics which was used to prevent or treat the infection from SARS-COV-2. Furthermore, cell-cultured models and engineered tissues had a major impact on investigating the infection, testing, and developing vaccines and therapeutics. Thus, the market resulted in varied designs of a range of diagnosis and therapeutic tools for the management of COVID-19, which includes rapid and accurate diagnostic platforms, novel vaccines, effective anti-viral drugs, and efficient models of laboratories for accessing the disease.
Technological advancements have made biomaterials more versatile and have increased their utility in various fields of healthcare, such as bioengineering and tissue engineering. The advent of smart biomaterials that interact with biological systems for several biomedical applications, such as from transport of bioactive molecules to cellular functioning of the engineered functional tissues, drives the revenue generation in this market. Companies are embracing the ongoing developments in novel drug delivery approaches for the controlled release of drugs, thus fueling the market growth. For instance, in January 2019, DSM Biomedical partnered with ProMed Pharma to leverage its biomedical biomaterials with ProMed’s micro molding and extrusion capabilities to create novel controlled-release drug implants and combination devices.
The porous-coated and fully or partially porous orthopedic implants have gained immense popularity in recent years. This is because the porous structures reduce the elastic modulus and stimulate bone growth around the implant. Powder metallurgy, 3-D printing, and additive manufacturing are some of the potential techniques to manufacture porous metallic and ceramic implants. Growing demand for smart biomaterials that produce and transfer bioelectric signals similar to native tissues for accurate physiological functions, is expected to surge the market growth. Piezoelectric scaffolds are smart materials that play a significant role in tissue engineering. They stimulate the signaling pathways and consequently improve tissue regeneration at the impaired site.
The polymer product segment dominated the market in terms of revenue at a share of 28.47% in 2022 and is expected to continue leading throughout the forecast period owing to the wide range of product applications. The wide availability of biopolymers and advanced polymers for bio-resorbable tissue fixation and other orthopedic applications is also expected to accelerate the revenue generation of the segment. Polymeric biomaterials are one of the cornerstones of tissue engineering. Ongoing progression in technologies, such as micro-manufacturing, surface modification, drug delivery, nanotechnology, and high-throughput screening, play an integral role in broadening polymeric material usage in the tissue engineering field.
Natural biomaterials are anticipated to witness the fastest CAGR of 17.51% from 2023 to 2030, owing to various benefits of the product over synthetic biomaterials in terms of biodegradability, biocompatibility, and remodeling. Due to these advantages, they are increasingly used to replace or restore the structure and function of damaged organs or tissues. For instance, biosensor, is an analytical device that is used to detect analytes such as biomolecules or biological elements of species produced by micro-organisms that is tissues, enzymes, organelles, etc. The sensor mainly consists of three parts that are, a bio-receptor (enzymes, antibodies, nucleic acids), a transducer (electrochemical, electrical, optical, thermal, magnetic resonance), and an electronic system that comprises a signal amplifier.
The orthopedic application segment dominated the biomaterials market in terms of revenue at a share of 23.15% in 2022. Increasing adoption of metallic biomaterials in orthopedic applications due to their high load-bearing capacity is one of the factors driving the segment growth. Besides, continuous developments for the introduction of advanced orthopedic implants by market vendors are also expected to propel the revenue generation. For instance, in November 2019, DiFusion Inc. received FDA approval for its Xiphos-ZF spinal interbody device, which is based on a different biomaterial Zfuze, a combination of poly-ether-ether-ketone and titanium. This new biomaterial leads to significant reductions of cytokine markers that cause inflammation and are associated with fibrous tissue formation.
Plastic surgery segment is expected to grow at the fastest CAGR of 16.99% during 2023-2030 owing to the increasing number of cosmetic procedures and increased usage of biomaterials in these surgeries. As per the 2019 publication of the International Society of Aesthetic Plastic Surgery, in the U.S., around 4.3 million cosmetic procedures were performed in 2018, which has positively influenced segment growth.
North America accounted for the largest share of 38.04% in 2022 owing to the initiatives undertaken by several public and private organizations. These include the National Science Foundation and the National Institute of Standards and Technology, which provide knowledge and assistance pertaining to biomaterials usage in biomedical applications. This has resulted in the expansion of biomaterials adoption in this region. Moreover, factors such as favorable government policies and the presence of several major market players in this region have contributed to the regional market share.
Asia Pacific is expected to register the highest CAGR of 16.71% during 2023-2030, owing to strategic initiatives adopted by the regional participants to reinforce their presence in local as well as global markets. For instance, in November 2019, a Japan-based company, Mitsubishi Chemical signed an agreement with U.S.-based AdvanSource Biomaterials to acquire their thermoplastic polyurethane elastomer business. This acquisition is expected to expand their business footprint globally and capture a significant share in the international market. In India, the biomaterials market is constantly booming. The Indian biomaterials industry is dominated by orthopedic, dental, and cardiovascular biomaterials. Increasing market shares of cardiovascular and orthopedic and biomaterial products are due to an increase in orthopedic surgery, cardiovascular surgeries, and dental procedures.
Key companies are making significant investments to expand their presence and maintain a competitive edge. They are also adopting strategies such as agreements, partnerships, and collaboration models to strengthen their product portfolio. Moreover, key vendors are inclined toward the development of more innovative products to expand their biomaterials offerings. For instance, in April 2023, Novo Nordisk collaborated with Aspect Biosystems, a company involved in bioprinting biomaterials, for the development of bioprinted tissue therapeutics for obesity and diabetes. Some of the prominent companies in the global biomaterials market include:
Medtronic plc
Evonik Industries AG
Carpenter Technology Corporation
Berkeley Advanced Biomaterials
Invibio Ltd.
Zimmer Biomet Holdings, Inc.
BASF SE
Covalon Technologies Ltd.
Stryker
Johnson & Johnson
Dentsply Sirona
CoorsTek Inc.
Corbion
Collagen Matrix, Inc.
Report Attribute |
Details |
Market size value in 2023 |
USD 178.02 billion |
Revenue forecast in 2030 |
USD 488.71 billion |
Growth rate |
CAGR of 15.52% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
May 2023 |
Revenue in USD billion and CAGR from 2023 to 2030 |
|
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Product, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait |
Key companies profiled |
Medtronic plc; Evonik Industries AG; Carpenter Technology Corporation; Berkeley Advanced Biomaterials; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; BASF SE; Covalon Technologies Ltd.; Stryker; Johnson & Johnson; Dentsply Sirona; CoorsTek Inc.;Corbion; Collagen Matrix, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global biomaterials market report on the basis of product, application, and region:
Product Outlook (Revenue, USD Billion, 2018 - 2030)
Metallic
Natural
Ceramics
Polymers
Application Outlook (Revenue, USD Billion, 2018 - 2030)
Cardiovascular
Sensors
Stents
Guidewires
Implantable Cardiac Defibrillators
Pacemakers
Vascular Grafts
Others
Ophthalmology
Synthetic Corneas
Intraocular Lens
Contact Lens
Ocular Tissue Replacement
Others
Dental
Tissue Regeneration Materials
Dental Implants
Bone Grafts & Substitutes
Dental Membranes
Others
Orthopedic
Joint Replacement Biomaterials
Orthobiologics
Bioresorbable Tissue Fixation Products
Viscosupplementation
Spine Biomaterials
Others
Wound Healing
Fracture Healing Device
Adhesion Barrier
Skin Substitutes
Internal Tissue Sealant
Surgical Hemostats
Others
Tissue Engineering
Plastic Surgery
Facial Wrinkle Treatment
Soft Tissue Fillers
Craniofacial Surgery
Bioengineered Skins
Peripheral Nerve Repair
Acellular Dermal Matrices
Others
Neurology
Neural Stem Cell Encapsulation
Shunting Systems
Hydrogel Scaffold For CNS Repair
Cortical Neural Prosthetics
Others
Others
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Thailand
Australia
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
b. The global biomaterials market size was estimated at USD 155.05 billion in 2022 and is expected to reach USD 178.02 billion in 2023.
b. The global biomaterials market is expected to grow at a compound annual growth rate of 15.52% from 2023 to 2030 to reach USD 488.71 billion by 2030.
b. The metallic product segment dominated the biomaterials market with a share of 40.92% in 2022. The wide availability of metallic and advanced materials for tissue fixation and other orthopedic applications is expected to accelerate segment revenue generation.
b. Some key players operating in the biomaterials market include Medtronic plc; Evonik Industries AG; Carpenter Technology Corporation; Berkeley Advanced Biomaterials; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; BASF SE; Covalon Technologies Ltd.; Stryker; Johnson & Johnson; Dentsply Sirona; CoorsTek Inc.;Corbion; and Collagen Matrix, Inc.
b. Key factors that are driving the biomaterials market growth include rising demand as a consequence of accidental injuries & chronic conditions, advances in biomaterials technologies, and expansion in the usage scope of biomaterials.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.